Decoding Neurological Disease. Building Medicines.

CELLTIUM is developing precision therapies for CMT1A and related peripheral neuropathies. By uniting deep biological insights with our proprietary PRECISION™ platform, we are accelerating the translation of discovery into disease-modifying therapies.

A New Model for Neurotherapeutics
At the core of our approach is an integrated discovery engine that combines quantitative phenotyping, multimodal data, and AI. This framework supports target identification, lead optimization, and data-driven decision-making from the outset.

Targeting the Core Biology
We are advancing a precision pipeline of mechanistically distinct small molecules designed to address the root causes of peripheral neuropathies. Rather than managing symptoms alone, our programs aim to restore nerve function and change the course of disease.

Partner With Us

We welcome strategic collaborations with investors and biopharma partners to advance our lead CMT1A program into the clinic and extend our platform across additional indications.

Interested in Our CMT1A Program?

MEET US AT

June 22–25, 2026 | San Diego, CA

April 28–30, 2026 | Seoul, KR

A New Model for Neurotherapeutics At the core of our approach is an integrated discovery engine that combines quantitative phenotyping, multimodal data, and AI. This framework supports target identification, lead optimization, and data-driven decision-making from the outset.

Targeting the Core Biology We are advancing a precision pipeline of mechanistically distinct small molecules designed to address the root causes of peripheral neuropathies. Rather than managing symptoms alone, our programs aim to restore nerve function and change the course of disease.

Interested in Our CMT1A Program?

A New Model for Neurotherapeutics
At the core of our approach is an integrated discovery engine that combines quantitative phenotyping, multimodal data, and AI. This framework supports target identification, lead optimization, and data-driven decision-making from the outset.

Targeting the Core Biology
We are advancing a precision pipeline of mechanistically distinct small molecules designed to address the root causes of peripheral neuropathies. Rather than managing symptoms alone, our programs aim to restore nerve function and change the course of disease.